In This Article Are We Are Going Share About Best Stocks Below RS 500 In India.
Before Going To Know About Best Stocks Below RS 500, If You Want To Invest In Any Company With Good Business. Don’t Stick By Seeing The Price Of The Stock.
Even If The Price Of The Stock Is Higher. Invest In It In Tranches, So That You Will Get Better Average Price.
Most Of The People Think That If They Buy 1000Rs Or Higher Price Shares They Will Get Less Quantity Like 10 Or 20. Or If They Buy Low Price Shares They Will Get More Quantity.
Quantity Doesn’t Matter, What Matters Is Quality. So Don’t Buy A Share By Thinking That If We Buy This Shares We Will Get More Quantity.
If The Fundamentals And Business Of The Company Are Well Then Blindly Invest In It In Tranches. Don’t Invest All Your Money At A Time. Let’s See About The Best Stocks Below RS 500.
Also read: ITC share price target 2022, 2025, 2030.
Best Stocks Below RS 500
Blindly Don’t Buy These Stocks, Further, Do Your Research And Invest. Because Even If You Invest Without Any Research If There Is A Fall In Market And The Stock Falls. You Will Not Have the Confidence To Hold The Stock Because You Don’t Know Much About The Company. Eventually By That Fear You Will Exit.
If You Have Done Further Research On Your Own, Even If The Stock Falls. Instead Of Panic You Will Have The Confidence To Add More Stocks At a Lower Price. Because You Have Done Your Own Research And Understood The Business Of The Company, So That You Will Confidence In The Company.
For Long Term Investment Confidence Is The Key. If You Have Confidence You Can Hold For Long Term Without Any Fear.
Also read: Reliance share price target 2022, 2025, 2030.
DXC Technology Acquired The Parent Company Of Xchanging Solutions, DXC Technology Is One Of The Globally Leading Company.
As The Company Bought The Parent Company Of Xchanging Solutions, Now The Company Has Became A Part Of DXC Technology.
Xchanging Solutions Is Currently Trading at 111 Rupees, The Stocks Is Below RS 500 And Has A Market Cap Of RS 1,175 Crores.
The Business Of Xchanging Solutions Include IT Outsourcing, Cloud Services, Security Services, Applications Development, And Maintenance And Provide Insurance BPAAS And BPO Services.
For The Insurance Product Of The Company Has Good Demand Globally. Every Time Xchanging Solutions Is In Top 10 Insurance Technology Provider.
Most Of The Indian IT Product Based Companies Have Grown So Much By Developing Insurance Based Products, Similarly, If The Xchanging Solutions Product Does Well Then Definitely We Can Expect Good Growth.
Also read: HFCL share price target 2022, 2025, 2030.
IF You Don’t Know About The Financial Ratios ROE, ROCE Or PE READ HERE
Currently, BIRLASOFT Is Trading at 410 Rupees And Has A Market Cap Of RS 11,461 Crores. It Is An IT Service Company.
If We The Revenue Mix Of BIRLASOFT. 37% Of The Revenues Are From Integrated Enterprise, 26% Of The Revenues Are From Digital Transformation, 20% Of The Revenues Are From Application Development And Maintenance And 17% Of The Revenues From SAP Services.
Recently The Company Started Hiring Heavily, If We Observe Past Trends, The Companies Hire Heavily Only When Are Expecting Good Future Growth.
The Company Is Generating A ROCE Of 21.5% And ROE Of 15.5% And The Company Is A Debt Free Company Which Is Generating Cash Consistently.
Also read: Tata power share price target 2022, 2025, 2030.
NOCIL Is A Chemical Company But The Growth Rate Of The Company Is Dependent On The Growth Of the Auto Segment. Because NOCIL Manufactures Rubber Chemicals.
Currently, NOCIL Is Trading at 263 Rupees And Has A Market Cap Of 4,387 Crores.
NOCIL Has 40% Market Share In India, Historically The Company Is Mostly Affected By Chinese Companies Because The Chinese Companies Used To Sell At Low Price.
So That NOCIL Also Need To Compete With Chinese Companies Which Results In Low Profits And Low-Profit Margins.
But Now The Scenarios Are Changing, With This Changes, The Company Is Going To Benefit A Lot.
The Company Is Also Expecting High Demand So That They Are Increasing Their Production Capacity. The Company Also Invested A Lot In Capex.
As They Are Manufacturing Rubber Chemicals Related To Tyres. As The Demand For Auto Segment Increases, We Can Expect Good Growth In NOCIL.
Revenues And Financials
66% Of The Revenues Are From Indian Market And 34% Of The Revenues Are From Rest Of The Worlds.
The Return Ratios Of The Company Are In Single Digits. This Is Mainly Because Of The Price War Between The Chinese Companies. At The Same Time From Past Few, Years Auto Segment Is Also Suffering Due To This Reasons. The Return Ratios OF The Company Are In Single Digits.
The Company ROCE Is 8.59% And ROE Is 7.07% And The Company Is Debt Free. These Are The Return Ratios Of The Company From Last Year. If We see Before Last Year The Return Ratios Are In Double Digits.
Also read: Urja Global share price target 2022, 2025, 2030.
CHOLAMANDALAM IN & FIN
Currently, The Stock Is Trading at 510 Rupees And Has A Market Cap Of RS 41,888 Crores.
The Loan Book Mix Of The Company Is 75% Off The Loans Are Vehicle Loans And 15% Of The Loans Are LAP (Loan Against Property).
The Company Is Maintaining 15.14% Tier 1 Capital And The Cost Of Borrowing Is 6.3%, Which Is Good. The Assets Under Management Stood At RS 76,518 Crores.
The Company Is Generating ROE Of 17.1%, The Company Also Delivered A Good Profit Growth Of 21.5% CAGR Over Last Five Years.
This Stock Is Benefiting From Ethanol Related Theme. Currently, The Stock Is Trading at 237 Rupees, Which Is The Stocks Below RS 500 And Has A Market Cap Of RS 1,077 Crores.
The Company Is Increasing Its Capacity Rapidly Due To The Demand For Ethanol.
36% Of The Revenues Are From Sorbitol & Sweetener, 19% Of The Revenues Are From Starch, 16% Of The Revenues Are From Calcium Carbonate, 15% Of The Revenues Are From By-Products And 13% Of The Revenues Are From Fructose.
The Company Has Generated a ROCE Of 25.6% And ROE Of 18.4% And The Company Is A Debt Free Company.
FDC Is Pharmaceuticals And Drugs Sector Company, It Is FMCG Type, Pharma Stock.
The current Market Price Of FDC Is 335 Rupees And Has A Market Cap Of 5,600 Crores. Most Of People May Don’t Know About FDC. Buy These Type Of Stocks Will Give Higher Returns Then Compared To Blu Chip Stocks.
Because Blue Chip Stocks Are Already Rallied A Lot And If You Want Higher Returns, You Need To Identify Good Fundamental Stocks. Which Are Not Yet Recognized By The Market.
Have You Ever Used Electral Powder ?, Most Of The People May Used It. Electral Powder Was Manufactured By FDC Limited. They Also Manufacture Various Other Popular Brands.
Currently, 20% Of The Revenues Are From Ophthalmology Segment And We Can Expect a Good Growth Rate From This Ophthalmology Segment.
Because Nowadays Everyone Was Sticking To Screens Like Mobile Phone, Laptops Or TVs. So Because Of This In Future There Will Be More Issues Related To Eye.
So Ophthalmology Segment Will Grow, As A Result, FDC Will Also See Good Growth In Their Ophthalmology Business.
89% Of The Revenues Are From Formulations And 4% Revenues From Bulk Drug. FDC Market share Is 1% In Indian Pharma Industry.
If We See The Revenues In Therapeutic Wise. 42% Of The Revenues Are From Anti-Infectives, 24% Revenues From Gastro-Intestinal( Stomach Related Problem ), 7% Of The Revenues From Minerals, Vitamins, And Nutrients, 6% From Ophthalmology And 6% Revenues From Cardiac.
If We See The Revenues In Location Wise 89% Of The Revenues Is From India and 11% From Rest Of The World.
The Company PE Ratio Is 18.61, Compared To Its Peer Companies The Company Is Trading At Good And Lower Valuations.
ROCE Of The Company Is 22.06%, ROE 16.59% The ROE And ROCE Are Also Good And The Company Is Performing Consistently And Currently Trading At Attractive Valuations.
It Has A Debt Of 5 Crores Which Is Negligible And The Company Is Maintaining an OPM ( Operating Profit Margin ) Of 25%.
The Financials Of The Stocks May Change Over Time, So If You Want Know The Financials Click Here And Search By Company Name.
HCG ( Healthcare Global Limited )
HCG Is Majorly Focused on Oncology And Fertility Related Treatments, They Also Offer Multi-Specialty Treatments. But Mainly Focused On Oncology And Fertility Related Treatments.
The Stock Is Currently Trading At 222 Rupees And Has A Market Cap Of 2,779 Crores.
Recently Management Has Changed And ACESO Has Acquired Majority Of The Stake In HCG Which Is About 58.92 Percent. When There Is A Management Change The Companies Will Tend To Perform Well.
If We See The Past Performance Or Numbers Of The Company, It May Not Be Attractive, But Due To Management Change And Entry Of Strong Management In Future The Company Will Perform Better.
The Therapies On Which They Are Focusing Will Have Good Demand. Because Cancer Has Became A Common Issue In Lot Of Families And The Treatment Cost Is Also High For Cancer Treatment. Fertility Issues Are Also Increasing And The Treatment-Related To Fertility Is Also Costly
As The Treatment Cost For Both Cancer And Fertility Issues Is Higher, The Average Daily Occupied Bed Revenue Will Also be High Compared To Other Hospitals Or Higher than The Average Of Other Hospitals.
Currently, 79% Of The Revenues Are From Oncology Segment And 7% Of The Revenue Is From Fertility Segment.
Operating Bed Capacity Of The Healthcare Global Is 1956 And Has Occupancy Ratio Of 45%. The Average Daily Revenue Per Occupied Bed Is About 34,788 Rupees.
The Debt To Equity Ratio Is 1.32
INDOCO Remedies Is Currently Trading At 452 Rupees And Has A Market Cap Of 4,157 Crores. It Is Also A Pharmaceutical & Drugs Sector Company.
If We See The Past Numbers Of INDOCO Remedies. The Performance Is Not Consistent As FDC Limited Because INDOCO Remedies Has Faced Some Regulated Issues. Like US FDA Alerts On Their Plants.
Due To These Issues The Company Had Lot Of Impact On Their Revenues And Profits. This Is The Reason For The Poor Past Performance Of The Company.
But Over A period The Company Is Solving All These Issues And Recently They Got Some Good Contracts From US And UK And Also Started Supplying.
In the Future, We Can Expect That The Company Will Post Good Numbers. The Company Also Have Some Popular Brands In Dental Segment Like KIDODENT, SENSOFORM. You May Used It Or Not, But If You Google It You Will About The Brands.
KARVOL Plus Is Also A Popular Brand Of This Company, Which Is Used For Cold, Cough And Asthma And Some Other Uses.
Revenues & Financials
89% Of The Revenues Are From Formulations, 8% Of The Revenue Is From API’s Segment. The ROE Of The Company Is 12.8% And ROCE Is 16%.
The Debt To Equity Ratio Is 0.28, Which Is Negligible.